LYV
ADAP

Live Your Vision’s Adaptimmune Therapeutics ADAP Stock Holding History

Live Your Vision’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$0 Hold
66
– – ﹤0.01% 265
2018
Q4 		$0 Buy
+66
New +$487 ﹤0.01% 250
2017
Q3 		– Sell
-50
Closed – – 270
2017
Q2 		$0 Hold
50
– – ﹤0.01% 297
2017
Q1 		$0 Buy
+50
New +$219 ﹤0.01% 297
2015
Q4 		– Sell
-1,500
Closed -$18K – 73
2015
Q3 		$18K Buy
+1,500
New +$21.2K 0.01% 155

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Live Your Vision's ADAP Position: Q1 2019 in Review

Live Your Vision held its Adaptimmune Therapeutics (ADAP) position steady in Q1 2019 at 66 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #265.

Live Your Vision first reported a position in ADAP in Q3 2015 and has held it in 5 quarters since. The position peaked at $18K in Q3 2015. 68 funds tracked by Wall St. Rank hold ADAP as of Q1 2019.

  • Live Your Vision held 66 shares of Adaptimmune Therapeutics worth $0 as of Q1 2019.
  • Live Your Vision left its Adaptimmune Therapeutics share count unchanged in Q1 2019.
  • Adaptimmune Therapeutics made up ﹤0.01% of Live Your Vision's portfolio in Q1 2019, its #265 holding.
  • Live Your Vision first reported a position in Adaptimmune Therapeutics in Q3 2015 and has held it in 5 quarters since.
  • Live Your Vision's Adaptimmune Therapeutics position peaked at $18K in Q3 2015.
  • 68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2019.

Based on Live Your Vision's 13F filing for Q1 2019, filed 25 Apr 2019.